Type 1: FDA OKs Levemir for Two- to Five-Year-Olds

| Jun 7, 2012

The US Food and Drug Administration has approved the use of Novo Nordisk's Levemir basal insulin for type 1 children aged two to five years. The FDA decision makes Levemir (insulin detemir [rDNA origin]) the only basal insulin approved for use in this age group.
Levemir, introduced to the US market in 2006, was previously approved for older children and adults with type 1 diabetes, as well as insulin-using type 2s.

The new FDA approval was based on Levemir's performance in reducing the risk of severe hypoglycemic episodes in the two-to-five year age group. Type 1 children in that group who received Levemir and a rapid-acting insulin analog, NovoLog (insulin aspart [rDNA origin] injection), experienced a lower rate of hypoglycemia than those taking NPH and NovoLog. None of the young patients treated with Levemir had a severe hypoglycemic episode, whereas six episodes were reported in three patients treated with NPH over the one-year study period.

Source: Novo Nordisk press release

Click Here To View Or Post Comments

Categories: Basal, Diabetes, Diabetes Health, FDA, Hypoglycemic Episodes, Insulin, Levemir, Novolog, Type 1, Type 1 Diabetes, Type 1 Issues


Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter

Latest
Popular
Top Rated
Print | Email | Share | Comments (0)

You May Also Be Interested In...


Click Here To View Or Post Comments

Comments 0 comments - Jun 7, 2012

©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.